Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.41 |
| ▸ | PDE4A | P27815 | 6/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.41 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207305 | 0.92 | CNR1 (0.41) | CNR2KMOABL1ANO1ALPL | |
| SCHEMBL19207261 | 0.91 | KDM5A (0.38) | KMOANO1KDM4CPOLBAPEX1 | |
| SCHEMBL19207308 | 0.89 | KMO (0.39) | CNR2PDE4DPDE4APDE4CPDE4B | |
| SCHEMBL19207300 | 0.89 | CSNK1D (0.35) | POLBCNR1 | |
| SCHEMBL19642047 | 0.88 | PDE4A (0.40) | CNR2PDE4DPDE4APDE4CPDE4B | |
| SCHEMBL19207284 | 0.87 | MAPT (0.40) | KDM4C | |
| SCHEMBL19207304 | 0.87 | CNR1 (0.45) | CNR2ALPLCNR1 | |
| SCHEMBL19207280 | 0.87 | CNR2 (0.40) | CNR2PDE4DPDE4APDE4CPDE4B | |
| SCHEMBL19207339 | 0.83 | CTRC (0.39) | KDM4C | |
| SCHEMBL19207276 | 0.83 | P2RY14 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473462-B | Pyrazole-pyridine derivatives as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | claimed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-29 | — | — | US | claimed |
| CN-108473462-B | Pyrazole-pyridine derivatives as EAAT3 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| EP-3411365-B1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-10457663-B2 | Pyrazol-pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3411365-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-12-12 | — | — | EP | disclosed |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-29 | — | — | US | disclosed |
| WO-2017133990-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017133990-A1 | PYRAZOL-PYRIDINE DERIVATIVES AS EAAT3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10457663-B2 | Pyrazol-pyridine derivatives | MC3R, MC2R, DRD3 | CNR2 416/4885PDE4D 2087/4885PDE4A 2314/4885 |
| US-20180339975-A1 | PYRAZOL-PYRIDINE DERIVATIVES | MC3R, MC2R, DRD3 | CNR2 416/4885PDE4D 2087/4885PDE4A 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.